Single-Pill Sofosbuvir and Daclatasvir for Treating Hepatis C in Patients Co-Infected With Human Immunodeficiency Virus Publisher Pubmed



Dehghan Manshadi SA¹ ; Merat S² ; Mohraz M¹ ; Rasoolinejad M¹ ; Sali S³ ; Mardani M³ ; Tabarsi P⁴ ; Somi MH⁵ ; Sedghi R⁵ ; Tayeri K¹ ; Nikbin M⁶ ; Karimi J⁷ ; Sharifi AH² ; Kalantari S⁸ Show All Authors Show Affiliations
Source: International Journal of Clinical Practice Published:2021

Abstract

Background: The current recommendation for treating hepatitis C virus (HCV) in HIV patients includes the combination of sofosbuvir (SOF) and daclatasvir (DCV). DCV should be used at different doses to compensate for interactions with antiretroviral therapy (ART). Up to three pills a day might be required which will significantly add to the pill burden of these patients. In this study, we have used a single-tablet approach to treating HCV-HIV coinfection. Methods: Patients coinfected with HIV and HCV were prospectively enrolled from 10 centers throughout the country. Patients received a single once-daily fixed dose combination (FDC) pill containing 400 mg SOF and 30, 60 or 90 mg DCV depending on the type of ART they were receiving for 12 or 24 weeks. (ClinicalTrials.gov ID: NCT03369327). Results: Two hundred thirty-three patients were enrolled from 10 centers. Twenty-three patients were lost to follow-up and two patients died from causes unrelated to treatment. Two hundred eight patients completed the treatment course of which 201 achieved SVR (96.6%). Conclusion: Single-tablet combination of DCV and SOF is an effective and safe treatment for patients coinfected with HIV and HCV. The combination works well in patients on ART in which dose adjustment is required. Patients with cirrhosis, previous treatment failure and various genotypes respond identically. The expenses of genotyping can be saved. © 2021 John Wiley & Sons Ltd